1) Craig WA:Pharmacokinetic/pharmacodynamic parameters;rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10, 1998
2) Moore RD, Lietman PS, Smith CR:Clinical response to aminoglycoside therapy;importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93-99, 1987
3) Naber KG:Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 17:331-341, 2001
4) 抗菌薬感受性測定法検討委員会報告(1997年):尿路感染症におけるブレイクポイント.日本化学療法学会雑誌 45:711-772, 1997
5) UTI研究会:UTI薬効評価基準(第3版).Chemotherapy 34:401-441, 1986
6) 日本化学療法学会臨床評価法制定委員会泌尿器系委員会:UTI薬効評価基準(第4版暫定案).日化療会誌 45:204-247, 1997
7) Milo G, Katchman EA, Paul M, et al:Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 18:CD004682, 2005
8) Carmignani G, De Rose AF, Olivieri L, et al:Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 74:326-331, 2005
9) Cox CE, Marbury TC, Pittman WG, et al:A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 24:223-236, 2002
10) Jaffe HW, Schroeter AL, Reynolds GH, et al:Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 15:587-591, 1979
11) Moran JS, Levine WC:Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 20 (Sup) 1:S47-65, 1995
12) 村谷哲郎・松本哲朗・新井進:Neisseria gonorrhoeaeに対するtelithromycinのin vitro抗菌力.Jpn J Antibiot 58:317-325, 2005